Detlev Mennerich

Detlev Mennerich is leading the Boehringer Ingelheim Venture Fund (BIVF) as Global Head. As PhD holder in Cell & Molecular Biology, Detlev joined Boehringer Ingelheim in 2005. As a co-inventor & project leader, he contributed to the approval of Spevigo for the treatment of Generalized Pustular Psoriasis. As Investment Director of the BI Venture Fund from 2014, he invested in groundbreaking therapeutics. He served on the boards of ViraTherapeutics & NBE Therapeutics until their respective acquisitions by Boehringer Ingelheim in 2018 & 2020.